The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
December 2019 (Volume 97)
Quarterly Article
Sara Rosenbaum
Oct 4, 2024
September 2024
Sep 18, 2024
Back to The Milbank Quarterly
The US Court of Appeals for the Ninth Circuit has long been sensitive to the role of courts in safeguarding individuals from threats to their health and well-being posed by potentially unlawful governmental policy. Thus, it came as no surprise that when the Trump administration issued its final Title X “gag” rule,1 most of the legal challenges were filed in Ninth Circuit trial courts. The rule would compel physicians to withhold essential information from patients regarding termination of pregnancy and would bar funding to any clinic that does not maintain complete physical separation between activities allowed and those (including full counseling and appropriate referrals) that the rule treats as promoting abortion.
In cases involving potentially unlawful government regulations that threaten health, the courts play an extraordinary role because of their power to stop such rules from taking effect while their legality is fully reviewed. This extraordinary power to temporarily halt governmental regulation is known as equity power, which traces its origins to the English Court of Chancery. Equity power plays an essential role in cases such as the Title X legal challenges, since if allowed to take effect prior to full review, the rule potentially could drive away large numbers of providers, with enormous access implications.
Equity power is not boundless; it hinges on certain prerequisites. Challengers must be able to show a likelihood of success on the legal merits—in other words, that their legal arguments have real power. Challengers also must be able to demonstrate real, irreparable injury if the government is allowed to proceed while the case is under review.
In the legal battle over the “gag” rule, three different federal courts in the Ninth Circuit, in three different cases brought by states, professional societies, and nonprofit health care providers,2 used their equity power to prohibit implementation before full trial. They did so after concluding, on a preliminary basis, that the challengers’ legal arguments against the rule were meritorious and, further, that the injury experienced by people and states were the rule to take effect pending the full trial would be irreparable. In their rulings, the lower courts acknowledged the US Supreme Court’s 1991 decision in Rust v Sullivan,3 upholding a virtual carbon copy “gag” rule issued by the Reagan administration. But the courts also concluded that, in the interim, federal law had changed in certain material ways, thereby calling into question Rust’s continued relevance. Furthermore, the courts found, in publishing the new rule, the administration had utterly disregarded a lengthy public comment record focusing in great part on its likely impact on the Title X provider network, access to care, and, ultimately, people’s health; such disregard amounted to a fatal flaw in agency rulemaking.
The trial courts also concluded that, based on the record, the rule likely would have widespread, adverse effects on the existing Title X provider network—not just Planned Parenthood (the largest and best-known Title X provider)—and could seriously undermine the continued participation by health professionals out of both legal and ethical concerns. Provider exodus, in turn, would jeopardize health care for millions of at-risk patients across the country, especially in medically underserved urban and rural areas. This would affect services such as family planning, screening and treatment of STDs, HIV screening, and cervical cancer screening. Irreparable harm would come in the form of delayed or no care, escalating rates of unintended pregnancies, and ultimately, increased rates of maternal mortality, infant mortality, and other adverse health outcomes that flow from the loss of access to services supported by Title X.4 Given the legally meritorious arguments and evidence of irreparable harm to people and states, the lower courts uniformly enjoined implementation of the rule at least pending full trial.
At this point, the Trump administration appealed to the Ninth Circuit, arguing that it be allowed to put the rule into effect immediately, prior to full trial. The administration argued that the earlier Supreme Court decision was legally dispositive, and that there was no likelihood of success on the merits. Since the legal claims had no merit, the administration argued, the trial courts acted improperly in halting implementation of the rule. Furthermore, the government stated, it had a direct interest in halting spending in violation of Title X (even though the record was utterly devoid of any evidence that any Title X funds had been improperly spent on abortion). For their part, the challengers pointed to their strong legal arguments as well as extensive evidence of harm.
To everyone’s astonishment, a three-judge Ninth Circuit panel sided with the government, and the full Ninth Circuit refused “en banc” to review further. On August 19th, the rule went into effect, meaning that family planning providers either now must show compliance or leave the program.
The unanimous three-judge panel’s decision was shocking on two counts. First, they discounted the evidence that the law had indeed changed since Rust, yet offered no analysis to refute the conclusion by the lower courts. The panel simply held that Rust “largely foreclosed” any attempt to challenge the new rule. Even more shocking was the panel’s conclusion that the federal government, not the millions of people who depend on Title X, would suffer greater harm without immediate implementation. The court based this extraordinary conclusion on the fact that “HHS will be forced to allow taxpayer dollars to be spent in a manner that it has concluded violates the law, as well as the Government’s important policy interest . . . in ensuring that taxpayer dollars do not go to fund or subsidize abortions.” In effect, the panel—indeed, the Ninth Circuit as a whole—simply ignored the record, which was replete with strong legal arguments, evidence of irreparable injury, and devoid of any evidence of misspending of Title X funds.
There is much speculation about why the Ninth Circuit took the unusual step of stripping away the protection of the preliminary injunction, given the evidence. We likely will never know. In the meantime, Planned Parenthood departed the program on August 19th. Multiple states also have announced their intent to withdraw, with plans to substitute their own funding for lost grants. Perhaps Planned Parenthood and other providers leaving the program will find alternative funds. But they may not—precisely the reason why the injunction was so critical. Indeed, based on past experience, loss of access is the likely result. In 2011, Texas similarly pushed highly qualified providers out of its family planning program; within a short period of time,5 health care access and health outcomes were seriously compromised for the very women—low income, at-risk, and medically underserved—who seem always to bear the burden of public health tragedies such as this.
References
Published in 2019 DOI: 10.1111/1468-0009.12421
Sara Rosenbaum J.D. is Emerita Professor of Health Law and Policy at George Washington University’s Milken Institute School of Public Health. Previously she served as the Harold and Jane Hirsh Professor of Health Law and Policy and as founding Chair of the Department of Health Policy.
Professor Rosenbaum has devoted her career to health justice for medically underserved populations. She is a member of the National Academies of Sciences, Engineering, and Medicine, served on CDC’s Director’s Advisory Committee and the CDC Advisory Committee on Immunization Practice (ACIP), and was a founding Commissioner of Congress’s Medicaid and CHIP Payment and Access Commission (MACPAC), which she chaired from January 2016 through April 2017.
Professor Rosenbaum is the recipient of many honors and awards including the National Academy of Medicine’s Adam Yarmolinsky Medal, awarded for distinguished service to a member from a discipline outside the health and medical sciences, the American Public Health Association Executive Director Award for Service, and the Association of Schools and Programs of Public Health Welch-Rose Award for Lifetime Contributions to the Health of the Public.